Skip Navigation

European Heart Journal 2000 21(8):639-646; doi:10.1053/euhj.1999.1755
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Glader, C.A
Right arrow Articles by Dahlén, G.H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glader, C.A
Right arrow Articles by Dahlén, G.H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae -specific IgG antibodies

C.A Gladera,f1, J Bomanb, P Saikkuc, H Stenlundd, L Weinehalld, G Hallmannsd and G.H Dahléna

a Departments of Clinical Chemistry, Umeå University, Sweden
b Virology, Umeå University, Sweden
d Public Health and Clinical Medicine, Umeå University, Sweden
c The National Public Health Institute, Oulu, Finland

revised June 15, 1999; accepted June 16, 1999

Abstract

Aims To investigate a possible relationship between the atherogenic properties of lipoprotein(a) (Lp(a)) and Chlamydia pneumoniae infections.

Methods and Results The study population was nested within the Västerbotten Intervention Program or the WHO MONICA project. In this incident case-control study, 78 patients who had suffered acute myocardial infarction and 156 matched controls were included. The contents of circulating immune complexes were analysed for C. pneumoniae IgG antibodies and Lp(a). A significantly larger proportion of cases than controls had ≥13mg.l–1Lp(a) and a C. pneumoniae specific IgG antibody titre ≥1/2 in circulating immune complexes (odds ratio=3·8).

Conclusion The proatherogenic effects of Lp(a) may be enhanced and/or partly mediated through the formation of circulating immune complexes containing C. pneumoniae -specific IgG antibodies. The connection between chronic C. pneumoniae infections and atherosclerosis may, at least in part, be explained by an interaction with Lp(a) through the formation of circulating immune complexes.

Key Words: Lipoprotein(a), Chlamydia pneumoniae, circulating immune complex, case-control study, acute myocardial infarction

f1 Correspondence: Christine Ahlbeck Glader, MD, Department of Clinical Chemistry, Ume University, SE-901 85 Ume, Sweden.

References

  1. Dahlén GH, Ericson C, Furberg C, Lundkvist L, Svärdsudd K. Studies on an extra pre-beta lipoprotein fraction. Acta Med Scan (Suppl). 1972;531:1–29
  2. Dahlén GH. Lipoprotein(a) as a risk factor for atherosclerotic diseases. Arctic Med Res. 1988;47:458–461
  3. Rhoads GG, Dahlén GH, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540–2544[Abstract/Free Full Text]
  4. Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AMJ. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758–765[Abstract/Free Full Text]
  5. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Quinici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51–61[CrossRef][Web of Science][Medline]
  6. Dahlén GH, Weinehall L, Stenlund H. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein-A1 is protective for the incidence of primary acute myocardial infarction in middle-aged males. J Intern Med. 1998;1998:425–430
  7. Weinehall, L, Partnership for health; On the role of primary health care in a community intervention programme. Ume, Sweden, Ume University
  8. Tunstall-Pedoe H. The World Health Organization MONICA Project (Monitoring of Trends and Determinants in Cardiovascular Disease): A major international collaboration. J Clin Epidemiol. 1988;:105–114
  9. Linnanmäki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 1993;87:1130–1134[Abstract/Free Full Text]
  10. Wang SP, Grayston JT. Microimmunofluorescense serological studies with the TWAR organism. Oriel JD, Ridgeway G, Schachter J, Taylor-Robinson D, Ward M. Chlamydial infections. Cambridge: Cambridge University Press; 1986. p. 329–332
  11. Hallqvist J, Ahlbom A, Diderichsen F, Reuterwall C. How to evaluate interaction between causes: a review of practices in cardiovascular epidemiology. J Intern Med. 1996;239:377–382[CrossRef][Web of Science][Medline]
  12. Rothman KJ. Interactions between causes. Modern epidemiology. Boston: Little, Brown; 1986. p. 315–20
  13. Saikku P, Leinonen M, Mattila K. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–986[Web of Science][Medline]
  14. Dahlén GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis. 1995;114:165–174[CrossRef][Web of Science][Medline]
  15. Grayston JT, Campbell LA, Kuo CC. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990;161:618–625[Web of Science][Medline]
  16. Campbell LA, O'Brien ER, Cappuccio AL. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis. 1995;172:585–588[Web of Science][Medline]
  17. Puolakkainen M, Kuo CC, Shor A, Wang SP, Grayston JT, Campbell LA. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol. 1993;31:2212–2214[Abstract/Free Full Text]
  18. Saikku P, Leinonen M, Tenkanen L. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273–278[Abstract/Free Full Text]
  19. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation. 1999;99:1161–1164[Abstract/Free Full Text]
  20. Moss TR, Darougar S, Woodland RM, Nathan M, Dines RJ, Cathrine V. Antibodies to Chlamydia species in patients attending a genitourinary clinic and the impact of antibodies to C. pneumoniae and C. psittaci on the sensitivity and the specificity of C. trachomatis serology tests. Sex Transm Dis. 1993;20:61–65[Web of Science][Medline]
  21. Ozanne G, Lefebvre J. Specificity of the microimmunofluorescence assay for the serodiagnosis of Chlamydia pneumoniae infections. Can J Microbiol. 1992;38:1185–1189[Web of Science][Medline]
  22. Kutlin A, Tsumura N, Emre U, Roblin PM, Hammerschlag MR. Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection. Clin Diagn Lab Immunol. 1997;4:213–216[Abstract]
  23. Füst G, Szondy É, Székely J, Nánai I, Gerö S. Studies on the occurrence of circulating immune complexes in vascular diseases. Atherosclerosis. 1978;29:181–190[CrossRef][Web of Science][Medline]
  24. Maisch B, Mayer E, Schubert U, Berg PA, Kochsiek K. Immune reactions in infective endocarditis. II. Relevance of circulating immune complexes, serum inhibition factors, lymphocytotoxic reactions, and antibody-dependent cellular cytotoxicity against cardiac target cells. Am Heart J. 1983;106:338–344[CrossRef][Web of Science][Medline]
  25. Gallagher PJ, Jones DB, Casey CR, Sharratt GP. Circulating immune complexes in cardiac disease. Atherosclerosis. 1982;44:241–244[CrossRef][Web of Science][Medline]
  26. Cristea A, Rus H, Niculescu F, Bedeleanu D, Vlaicu R. Characterization of circulating immune complexes in heart disease. Immunol Lett. 1986;13:45–49[CrossRef][Web of Science][Medline]
  27. Farrell C, Bloth B, Nielsen H, Daugharty H, Lundman T, Svehag SE. A survey for circulating immune complexes in patients with acute myocardial infarction. Use of a C1q-binding assay with soluble protein A as indicator. Scand J Immunol. 1977;6:1233–1240[Web of Science][Medline]
  28. Smith GW, McArthur CJ, Simpson IJ. Circulating immune complexes in myocardial infarction. J Clin Lab Immunol. 1983;12:197–199[Web of Science][Medline]
  29. Tertov VV, Orekhov AN, Sayadyan KS. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis. 1990;81:183–189[CrossRef][Web of Science][Medline]
  30. McLean JW, Tomlinson JE, Kuang WJ. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132–137[CrossRef][Medline]
  31. Dahlén GH. Indications of an autoimmune component in Lp(a) associated disorders. Eur J Immunogenet. 1994;21:301–312[Web of Science][Medline]
  32. Young, CL, Baker, WC, Tomaselli, CM, Dayhoff, MO, Serine Proteases, Dayhoff, MO, Atlas of protein sequence and structure. Silver Spring, MD, National Biomedical Research Foundation, 1978, 5, 73
  33. Dahlén GH, Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet. 1997;52:272–280[Web of Science][Medline]
  34. Kaukoranta Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog. 1996;:215–221
  35. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13:1501–1504[Abstract/Free Full Text]
  36. Gianturco SH, Bradley WA, Dahlén GH. Interaction of lipoprotein(a) with murine peritoneal macrophages and cultured human fibroblasts (Abstr). Arteriosclerosis. 1983;3:500a

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
J. Parratt, R. Tavendale, J. O'Riordan, D. Parratt, and R. Swingler
Chlamydia pneumoniae-specific serum immune complexes in patients with multiple sclerosis
Multiple Sclerosis, April 1, 2008; 14(3): 292 - 299.
[Abstract] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
T. Iwamoto, S. Fukuda, S. Shimizu, and M. Takasaki
Long-Term Effects of Lipoprotein(a) on Carotid Atherosclerosis in Elderly Japanese
J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2004; 59(1): M62 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. P. Higgins
Chlamydia pneumoniae and Coronary Artery Disease: The Antibiotic Trials
Mayo Clin. Proc., March 1, 2003; 78(3): 321 - 332.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
C.A Glader, L.S Birgander, S Soderberg, H.P Ildgruben, P Saikku, A Waldenstrom, and G.H Dahlen
Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis
Eur. Heart J., January 2, 2003; 24(2): 198 - 208.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
B. Tarnacka, G. Gromadzka, and A. Czlonkowska
Increased Circulating Immune Complexes in Acute Stroke: The Triggering Role of Chlamydia pneumoniae and Cytomegalovirus
Stroke, April 1, 2002; 33(4): 936 - 940.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
C. Stollberger and J. Finsterer
Role of Infectious and Immune Factors in Coronary and Cerebrovascular Arteriosclerosis
Clin. Vaccine Immunol., March 1, 2002; 9(2): 207 - 215.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
J. Danesh, P. Whincup, S. Lewington, M. Walker, L. Lennon, A. Thomson, Y.-K. Wong, X. Zhou, and M. Ward
Chlamydia pneumoniae IgA titres and coronary heart disease. Prospective study and meta-analysis
Eur. Heart J., March 1, 2002; 23(5): 371 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Tavendale, D. Parratt, S.D. Pringle, R. A'brook, and H. Tunstall-Pedoe
Serological markers of Chlamydia pneumoniae infection in men and women and subsequent coronary events. The Scottish Heart Health Study Cohort
Eur. Heart J., February 2, 2002; 23(4): 301 - 307.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
J. Boman and M. R. Hammerschlag
Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies
Clin. Microbiol. Rev., January 1, 2002; 15(1): 1 - 20.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Hoffmeister, D. Rothenbacher, G. Bode, K. Persson, W. Marz, M. A. Nauck, H. Brenner, V. Hombach, and W. Koenig
Current Infection With Helicobacter pylori, but Not Seropositivity to Chlamydia pneumoniae or Cytomegalovirus, Is Associated With an Atherogenic, Modified Lipid Profile
Arterioscler Thromb Vasc Biol, March 1, 2001; 21(3): 427 - 432.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
J. Danesh, P. Whincup, M. Walker, L. Lennon, A. Thomson, P. Appleby, Y.-k. Wong, M. Bernardes-Silva, M. Ward, and R. West
Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis Commentary: Adjustment for potential confounders may have been taken too far
BMJ, July 22, 2000; 321(7255): 208 - 213.
[Abstract] [Full Text]

Home page
 Eur Heart JHome page
A. Cassone
Chlamydia pneumoniae and lipoprotein(a): the right combination for atherosclerosis?
Eur. Heart J., April 2, 2000; 21(8): 599 - 600.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Glader, C.A
Right arrow Articles by Dahlén, G.H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glader, C.A
Right arrow Articles by Dahlén, G.H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?